Key result
Greater than mild tricuspid regurgitation independently predicted structural disease progression, including a >10% drop in fractional area change (HR 3.51; 95% CI 1.77-6.95).
Why the study?
Prior studies evaluating structural and electrocardiographic changes in arrhythmogenic right ventricular cardiomyopathy and their role in predicting ventricular arrhythmias have shown conflicting results.
Cohort (n=64)
Hazard Ratio: 3.51 (95% CI 1.77–6.95)
In patients with arrhythmogenic right ventricular cardiomyopathy, tricuspid regurgitation is an independent predictor of structural disease progression, which may be exacerbated by transvenous ICD leads and correlates with ventricular tachycardia risk.
Hypothesis-generating for arrhythmia predictors in ARVC; prospective validation needed before clinical adoption.
BACKGROUND: Prior studies of structural and electrocardiographic changes in arrhythmogenic right ventricular (RV) cardiomyopathy and their role in predicting ventricular arrhythmias (ventricular tachycardia) have shown conflicting results. METHODS: We reviewed 405 ECGs, 315 transthoracic echocardiographies, and 441 implantable cardioverter defibrillator interrogations in 64 arrhythmogenic RV cardiomyopathy patients (56% men, mean age [SD], 44.2 [14.6] years) over a mean follow-up of 10 (range, 2.3-19) years. Generalized estimating equations were used to identify the association between ECG abnormalities, clinical variables, and transthoracic echocardiographic measurements (>mild degree of tricuspid regurgitation, RV outflow tract diameter in parasternal long axis and short axis, RV end-diastolic area, fractional area change). RESULTS: There was a 4.65 (95% CI, 0.51%-8.8%) increase in RV end-diastolic area, a 3.75 (95% CI, 1.17%-6.34%) decrease in fractional area change, and 1.9 (95% CI, 1.3-2.8) higher odds (odds ratio) of RV wall motion abnormality with every 5-year increase in age after patients' first transthoracic echocardiography. >Mild tricuspid regurgitation was an independent predictor of RV enlargement and dysfunction (hazard ratio of >10% drop in fractional area change from baseline [95% CI], 3.51 [1.77-6.95] and hazard ratio of >10% increase in RV end-diastolic area from baseline [95% CI], 4.90 [2.52-9.52]). Patients with implantable cardioverter defibrillator were more likely to develop >mild tricuspid regurgitation and larger structural and functional disease progression. More pronounced increase in RV end-diastolic area was translated into higher rates of any ventricular tachycardia. Inferior T-wave inversions and sum of R waves (mm) in V1 to V3 were predictors of RV enlargement and dysfunction with the former also predicting risk of any ventricular tachycardia. CONCLUSIONS: Arrhythmogenic RV cardiomyopathy is a progressive disease. Tricuspid regurgitation is an independent predictor of structural disease progression, which may be exacerbated by use of a transvenous implantable cardioverter defibrillator lead.
No takes yet. Share an insight, caveat, or question.
Kalantarian et al. (2021) conducted a cohort in Arrhythmogenic right ventricular cardiomyopathy (n=64). >Mild tricuspid regurgitation vs. ≤Mild tricuspid regurgitation was evaluated on >10% drop in fractional area change from baseline (HR 3.51, 95% CI 1.77-6.95). Greater than mild tricuspid regurgitation independently predicted structural disease progression, including a >10% drop in fractional area change (HR 3.51; 95% CI 1.77-6.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: